Application of Dendrimer-based Nanoparticles in Glioma ImagingSunalee Gonawala1 and Meser M Ali1,2*
- *Corresponding Author:
- Meser M Ali
Department of Neurology
Henry Ford Hospital, Detroit
MI 48202, USA
E-mail: [email protected]
Received Date: May 23, 2017; Accepted Date: June 07, 2017; Published Date: June 14, 2017
Citation: Gonawala S, Ali MM (2017) Application of Dendrimer-based Nanoparticles in Glioma Imaging. J Nanomed Nanotechnol 8: 444. doi: 10.4172/2157-7439.1000444
Copyright: © 2017 Gonawala S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dendritic polymers or dendrimers present an alternate template for the development of nanoparticulate-based drug delivery and imaging systems. The smaller size (∼7-12 nm) of dendrimers have the advantage over the other particles, because its smaller size can possibly improve tumor penetration and the inclusion of tumor specific drug release mechanisms. A Paramagnetic Chemical Exchange Saturation Transfer (PARACEST) MRI contrast agent, Eu- DOTA-Gly4 or a clinical relevant Gd-DOTA was conjugated on the surface of a G5 PAMAM dendrimer. To create a dual mode MRI-optical imaging nanoparticle, Dylight680 was also incorporated on the amines surface of a G5 dendrimer. The particle was detected with in vivo MRI in preclinical glioma animal model. Furthermore, noninvasive imaging results were validated with in vivo and ex-vivo optical imaging.